Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials

Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter, phase II trial in previously treated WM patients. We sought to evaluate whether there were differences in clinical characteristics, response, and...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hemasphere
Autori principali: Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wolters Kluwer Health 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7306303/
https://ncbi.nlm.nih.gov/pubmed/32647793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000363
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi